Roche Holding AGCHIX:ROZ -0.70%77 Days Payable is 92.41 as of Dec. 2025, which is 34% above its 10-year median of 68.88. GuruFocus rates CHIX:ROZ with a GF Score™ of 77/100 and a GF Value™ of CHF268.31 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 923 Drug Manufacturers companies, Roche Holding AG ranks better than 52% on this metric.
The historical rank and industry rank for Roche Holding AG's Days Payable or its related term are showing as below:
CHIX:ROz'
s Days Payable Range Over the Past 10 Years
Min: 54.96 Med: 68.88 Max: 93.07
Current: 93.07
During the past 13 years, Roche Holding AG's highest Days Payable was 93.07. The lowest was 54.96. And the median was 68.88.
CHIX:ROz's Days Payable is ranked better than 52% of 923
companies
in the Drug Manufacturers industry
Industry Median: 90.98
vs CHIX:ROz: 93.07
Roche Holding AG's Days Payable
increased
from Dec. 2024 (86.53) to Dec. 2025 (92.41).
It may suggest that Roche Holding AGdelayed paying its suppliers.
Roche Holding AG Days Payable Related Terms
Roche Holding AG Days Payable Historical Data
* Premium members only.
The historical data trend for Roche Holding AG's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:ROZ vs LLY, JNJ, ABBV: Days Payable Comparison
For the Drug Manufacturers - General subindustry, Roche Holding AG's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Roche Holding AG Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Roche Holding AG's Days Payable distribution charts can be found below:
* The bar in red indicates where Roche Holding AG's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Roche Holding AG's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Roche Holding AG (CHIX:ROZ) has a Days Payable of 92.41 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Roche Holding AG and its competitors. This is 34% above median its historical median of 68.88. Over the past decade, Roche Holding AG's Days Payable has ranged from 54.96 to 93.07. According to the industry distribution chart, Roche Holding AG ranks #443 out of 923 companies in the Drug Manufacturers industry, placing it in the top 48%.
Is Roche Holding AG's Days Payable too high?
Roche Holding AG's current Days Payable of 92.41 is 34% above median its 10-year median of 68.88. Over the past 10 years, this metric has ranged from a low of 54.96 to a high of 93.07. The Drug Manufacturers industry median Days Payable is 90.98. Roche Holding AG's value of 92.41 is 1.6% above this industry median. Based on the distribution chart, Roche Holding AG ranks #443 out of 923 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Roche Holding AG has a GF Score™ of 77/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Roche Holding AG's Days Payable compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Roche Holding AG ranks #443 out of 923 companies for Days Payable. This puts Roche Holding AG in the upper half of its industry. The industry median Days Payable is 90.98. Roche Holding AG's value of 92.41 is 1.6% above this benchmark. Historically, Roche Holding AG's own Days Payable has ranged from 54.96 to 93.07 over the past decade. While the company's 10-year median is 68.88 vs. the industry median of 90.98, Roche Holding AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.98, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Roche Holding AG's current Days Payable of 92.41 is 1.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Roche Holding AG and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Roche Holding AG's current Days Payable is 92.41, which is 34% above median its own 10-year median of 68.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Roche Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Roche Holding AG (CHIX:ROZ) is currently considered Modestly Overvalued. The stock's GF Value™ is CHF268.31, compared to a current price of CHF340.60 — trading 26.9% above its estimated fair value. The current Days Payable is 92.41, which is 34% above median its 10-year median of 68.88 and 1.6% above the Drug Manufacturers industry median of 90.98. Roche Holding AG's overall GF Score™ is 77/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Roche Holding AG (CHIX:ROZ), the current Days Payable is 92.41 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Roche Holding AG (CHIX:ROZ) Overvalued in 2026?
Based on GuruFocus' analysis, Roche Holding AG stock appears to be overvalued.
The current stock price of CHF340.60 is trading 26.9% above its estimated GF Value™ of CHF268.31.
GuruFocus considers Roche Holding AG to be Modestly Overvalued.
Key valuation signals for CHIX:ROZ:
Days Payable: 92.41 (34% above median its 10-year median of 68.88)
GF Value™: CHF268.31 vs. price of CHF340.60 (26.9% above fair value)
Industry Position: 1.6% above the Drug Manufacturers median (#443 of 923)
No single metric tells the full story. See the CHIX:ROZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 40% of pharmaceutical sales, and centralized and point-of-care diagnostics for two-thirds of diagnostic-related sales.
77GF Score
Get the complete analysis for CHIX:ROZ
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:ROZ has been successfully added to your 
